Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f1 allergy

SummaryWe have previously shown that the major dog allergen Can f1 contains seven T cell epitope regions, none of which was preferentially recognized. To identify the immune characteristics of Can f1 epitopes and to verify their suitability for peptide-based allergen immunotherapy, short-term T cell lines were generated with epitope-containing peptides from peripheral blood mononuclear cells of Can f1 skinprick test-positive allergic and healthy control subjects. The lines were examined for their proliferative capacity and cytokine production upon stimulation with the allergen peptide, a homologous peptide from human tear lipocalin (TL) and Can f1 and TL proteins. Can f1 peptides induced proliferation of T cells and gave rise to T cell lines with comparable efficiencies. In particular, the T cell lines of allergic subjects induced with p33-48 and p107-122 favoured the production of interferon-g and interleukin-10, respectively. A greater number of Can f1-specific T cell lines were generated from allergic than from healthy individuals. Two p107-122-induced Can f1-specific T cell lines also reacted to a homologous peptide of human TL. Our results suggest that several T cell epitope-containing peptides should be used in combination for specific immunotherapy in Can f1 allergy.